Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Aligos Therapeutics, Inc.

NASDAQ: ALGS · Life Sciences · 3 alerts · CIK 1799448

Share price
$1.66Close, Nov 16
Sector
Life Sciences
Industry
Biological Products, (No Diagnostic Substances)SIC 2836

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Aligos Therapeutics, Inc. filings on SEC EDGAR ↗

8:08 AM ET 10-Q
Financial Results

Aligos Therapeutics Q3 2026 Results: Net Loss of $21.9M, Loss Narrows

For the nine months ended September 30, 2026, Aligos Therapeutics reported a net loss of $46.4 million, a significant increase from the $4.3 million loss in the prior year period. While total revenue grew to $33.5 million due to a $27.8 million licensing agreement, the prior year's results were heavily skewed by a $59.0 million non-cash gain from the change in fair value of common warrants.

Key figure
Net loss $21.9M
8:01 AM ET 8-K
Financial Results

Aligos Therapeutics Financial Results

Aligos Therapeutics reported third quarter 2026 financial results, including a net loss of $21.9 million and a cash position of $31.1 million. The company highlighted clinical progress in its Phase 2 B-SUPREME study of pevifoscorvir sodium, which remains on track for a topline data readout in late Q3 2027. Current cash reserves are expected to fund operations into the first quarter of 2027.

“This past quarter we continued to advance our Phase 2 B-SUPREME study of pevifoscorvir sodium, which remains on track for the topline data readout in late Q3 2027. With enrollment complete and 70 participants having completed 48 weeks of treatment, the study continues to progress toward the anticipated topline data readout. We remain enthusiastic about pevifoscorvir sodium’s potential, as well as our ASO ALG-170675, which is currently in a Phase 1 study in China with our partner Amoytop. With these recent developments, we believe we are one step closer to our goal of bringing effective therapies to people living with chronic HBV infection.”

Lawrence Blatt, Ph.D., M.B.A., Chairman, President, and Chief Executive Officer
4:03 PM ET 8-K
Other 8-K Filing

Aligos Therapeutics Other 8-K Filing

Aligos Therapeutics entered into a first amendment to its headquarters lease in South San Francisco, extending the term from March 2027 to March 2034. The amendment sets a graduated monthly base rent starting at $4.650 per square foot and includes a ten-month rent abatement period and a one-time termination option in 2031.

Counterparty
Britannia Biotech Gateway Limited Partnership
Term
7 years

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.